Endomyocardial Biopsy and Natural History of Myocarditis

Heart Failure Clinics

Volumn 1, Issue 3, 2005, Pages 391-406

  Narula, Navneet ^a   McNamara, Dennis M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOSPORIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INOTROPIC AGENT; LOOP DIURETIC AGENT; METHOTREXATE; OKT 3; STEROID; THIAZIDE DIURETIC AGENT;

ACUTE RHEUMATIC CARDITIS; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DISEASE COURSE; EOSINOPHIL MYOCARDITIS; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE BIOPSY; HEART VENTRICLE FUNCTION; HELMINTH; HUMAN; INFLAMMATION; INTERSTITIAL MYOCARDITIS; LYMPHOCYTIC MYOCARDITIS; MYOCARDITIS; PATHOGENESIS; PREVALENCE; PROTOZOON; REVIEW; SARCOIDOSIS; SCHISTOSOMIASIS;

ANIMALS; BIOPSY; DIAGNOSIS, DIFFERENTIAL; EOSINOPHILS; GENETIC PREDISPOSITION TO DISEASE; GIANT CELLS; HUMANS; LYMPHOCYTES; MYOCARDITIS; MYOCARDIUM; RHEUMATIC FEVER; SARCOIDOSIS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33645976166     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2005.06.016     Document Type: Review

References (126)

1. Sakakibara S., and Konno S. Endomyocardial biopsy. Jpn Heart J 3 (1962) 537-543
2. Edwards W.D. Current problems in establishing quantitative histopathologic criteria for the diagnosis of lymphocytic myocarditis by endomyocardial biopsy. Heart Vessels Suppl 1 (1985) 138-142
3. Feeley K.M., Harris J., and Suvarna S.K. Necropsy diagnosis of myocarditis: a retrospective study using CD45RO immunohistochemistry. J Clin Pathol 53 (2000) 147-149
4. Edwards W.D., Holmes D.R., and Reeder G.S. Diagnosis of active lymphocytic myocarditis by endomyocardial biopsy: quantitative criteria for light microscopy. Mayo Clin Proc 57 (1982) 419-425
5. Kuhl U., Noutsias M., and Schultheiss H.P. Immunohistochemistry in dilated cardiomyopathy. Eur Heart J 16 (1995) 100-106
6. Herskowitz A., Ahmed-Ansari A., Neuman D.A., et al. Induction of major histocompatibility complex antigens within the myocardium of patients with active myocarditis: a non-histologic marker of myocarditis. J Am Coll Cardiol 15 (1990) 624-632
7. Aretz H.T., Billingham M.E., Edwards W.D., et al. Myocarditis: a histopathologic definition and classification. Am J Cardiovasc Pathol 1 (1987) 3-14
8. Bowles N.E., Ni J., Kearney D.L., et al. Detection of viruses in myocardial tissues by polymerase chain reaction evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol 42 (2003) 466-472
9. Eckart R.E., Love S.S., Atwood J.E., et al. Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. J Am Coll Cardiol 44 (2004) 201-205
10. Felker G.M., Hu W., Hare J.M., et al. The spectrum of dilated cardiomyopathy: the Johns Hopkins experience with 1,278 patients. Medicine (Baltimore) 78 (1999) 270-283
11. Mason J.W., O'Connell J.B., Herskowitz A., et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 333 (1995) 269-275
12. Frustaci A., Chimenti C., Calabrese F., et al. Immunosuppressive therapy for active lymphocytic myocarditis. Circulation 107 (2003) 857-863
13. McCarthy R.E., Boehmer J.P., Hruban R.H., et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 342 (2000) 690-695
14. Arima M., and Kanoh T. Eosinophilic myocarditis associated with dense deposits of eosinophilic cationic protein (ECP) in endomyocardium with high serum ECP. Heart 81 (1999) 669-671
15. Corradi D., Vaglio A., Maestri R., et al. Eosinophilic myocarditis in a patient with idiopathic hypereosinophilic syndrome: insights into mechanisms of myocardial cell death. Hum Pathol 35 (2004) 1160-1163
16. Terasaki F., Hayashi T., Hirota Y., et al. Evolution to dilated cardiomyopathy from acute eosinophilic pancarditis in Churg-Strauss syndrome. Heart Vessels 12 (1997) 43-48
17. Lanham J.G., Cooke S., Davies J., et al. Endomyocardial complications of the Churg-Strauss syndrome. Postgrad Med J 61 (1985) 341-344
18. Gravanis M.B., Hertzler G.L., Franch R.H., et al. Hypersensitivity myocarditis in heart transplant candidates. J Heart Lung Transplant 10 (1991) 688-697
19. Takkenberg J.J., Czer L.S., Fishbein M.C., et al. Eosinophilic myocarditis in patients awaiting heart transplantation. Crit Care Med 32 (2004) 888-890
20. Aggarwal A., Bergin P., Jessup P., et al. Hypersensitivity myocarditis presenting as cardiogenic shock. J Heart Lung Transplant 11 (2001) 1241-1244
21. Grabellus F., Mall G., Schnabel P.A., et al. Immunohistochemical differentiation of eosinophilic heart diseases using antibodies against eosinophilic activation markers. Histopathology 46 (2005) 89-97
22. Davidson R.A. Immunology of parasitic infections. Med Clin North Am 69 (1985) 751-758
23. Shariff S., Straatman L., Allard M., et al. Novel associations of giant cell myocarditis: two case repots and review of literature. Can J Cardiol 5 (2004) 557-561
24. Daniles P.R., Berry G.J., Tazelaar H.D., et al. Giant cell myocarditis as a manifestation of drug hypersensitivity. Cardiovasc Pathol 9 (2000) 287-291
25. Shields R.C., Tazelaar H.D., Berry G.J., et al. The role of right ventricular endomyocardial biopsy for idiopathic giant cell myocarditis. J Card Fail 8 (2002) 74-78
26. Litovsky S.H., Burke A.P., and Virmani R. Giant cell myocarditis: an entity distinct from sarcoidosis characterized by multiphasic myocyte destruction by cytotoxic T cells and histiocytic giant cells. Mod Pathol 9 (1996) 1126-1134
27. Cooper L.T., Berry G.J., Shabetai R., et al. Idiopathic giant-cell myocarditis: natural history and treatment. N Engl J Med 336 (1997) 1860-1866
28. Cooper L.T., and Okura Y. Idiopathic giant cell myocarditis. Curr Treat Options Cardiovasc Med 3 (2001) 463-467
29. Davies R.A., Veinot J.P., Smith S., et al. Giant cell myocarditis: clinical presentation, bridge to transplantation with mechanical circulatory support, and long-term outcome. J Heart Lung Transplant 21 (2002) 674-679
30. Singh T.P., Rabah R., Cooper L.T., et al. Total lymphoid irradiation: new therapeutic option for refractory giant cell myocarditis. J Heart Lung Transplant 23 (2004) 492-495
31. Thomas P.D., and Hunninghake G.W. Current concepts of the pathogenesis of sarcoidosis. Am Rev Respir Dis 135 (1987) 747-760
32. Harrington D., Major M., Rybicki B., et al. Familial sarcoidosis: analysis of 91 families. Sarcoidosis 11 (1994) 240-243
33. Silverman K.J., Hutchins G.M., and Bulkley B.H. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 58 (1978) 1204-1211
34. Matsui Y., Iwai T., Tachibana T., et al. Clinicopathological study of fatal myocardial sarcoidosis. Ann N Y Acad Sci 278 (1976) 455-469
35. Nelson J.E., Kirschner P.A., and Teirstein A.S. Sarcoidosis presenting as heart disease. Sarcoidosis Vasc Diffuse Lung Dis 13 (1996) 178-182
36. Shiraishi J., Tatsumi T., Shimoo K., et al. Cardiac sarcoidosis mimicking right ventricular dysplasia. Jpn Circ J 67 (2003) 169-171
37. Matsumori A., Hara M., Nagai S., et al. Hypertrophic cardiomyopathy as a manifestation of cardiac sarcoidosis. Jpn Circ J 64 (2000) 679-683
38. Sekiguchi M., Yazaki Y., Isobe M., et al. Cardiac sarcoidosis: diagnostic, prognostic and therapeutic considerations. Cardiovasc Drugs Ther 10 (1996) 495-510
39. Becker D., Berger E., and Chmielewski C. Cardiac sarcoidosis: a report of four cases with ventricular tachycardia. J Cardiovasc Electrophysiol 1 (1990) 214-219
40. Paz H.L., McCormick D.J., Kutalek S.P., et al. The automated implantable cardiac defibrillator: prophylaxis in cardiac sarcoidosis. Chest 106 (1994) 1603-1607
41. Oni A.A., Hershberger R.E., Norman D.J., et al. Recurrence of sarcoidosis in a cardiac allograft: control with augmented corticosteroids. J Heart Lung Transplant 11 (1992) 367-369
42. Fenderson P.G., Fischetti V.A., and Cunningham M.W. Tropomyosin shares immunologic epitopes with group A streptococcal M proteins. J Immunol 142 (1989) 2475-2481
43. Li Y., Pan Z., Ji Y., et al. Enterovirus replication in valvular tissue from patients with chronic rheumatic heart disease. Eur Heart J 23 (2002) 567-573
44. Narula J., Chopra P., Talwar K., et al. Does endomyocardial biopsy aid in the diagnosis of active rheumatic carditis?. Circulation 88 (1993) 2198-2205
45. Shirani J., Freant L.J., and Roberts W.C. Gross and semiquantitative histologic findings in mononuclear cell myocarditis causing sudden death, and implications for endomyocardial biopsy. Am J Cardiol 72 (1993) 952-957
46. Chow L.H., Radio S.J., Sears T.D., et al. Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. J Am Coll Cardiol 14 (1989) 915-920
47. Frustaci A., Belloci F., and Osen E.G. Results of biventricular endomyocardial biopsy in survivors of cardiac arrest with apparently normal hearts. Am J Cardiol 74 (1994) 890-895
48. Parillo J.E., Cunnion R.E., Epstein S.E., et al. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 321 (1989) 1061-1068
49. Drucker N.A., Colan S.D., Lewis A.B., et al. Gammaglobulin treatment of acute myocarditis in the pediatric population. Circulation 89 (1994) 252-257
50. Bozkurt B., Villanueva F.S., Tokarczyk T., et al. Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol 34 (1999) 177-180
51. McNamara D.M., Holubkov R., Starling R.C., et al., for the IMAC Investigators. A controlled trial of intravenous immune globulin for recent onset dilated cardiomyopathy. Circulation 103 (2001) 2254-2259
52. Hufnagal G., Pankuweit S., Schonian U., et al. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). First epidemiology results. Herz 25 (2000) 279-285
53. Saphir O. Myocarditis, a general review with an analysis of 240 cases. Arch Pathol 32 (1951) 1000
54. Gore E., and Saphir O. Myocarditis, a classification of 1402 cases. Am Heart J 34 (1947) 827-830
55. Blankenhorn M.A., and Gall E.A. Myocarditis and myocardosis: a clinicopathologic appraisal. Circulation X111 (1956) 217-223
56. Drory Y., Turetz Y., Hiss Y., et al. Sudden unexpected death in persons less than 40 years of age. Am J Cardiol 68 (1991) 1388-1392
57. Huber S.A. Animal models: immunological aspects. In: Banatvala J.E. (Ed). Viral infections of the heart (1993), Arnold, London 82-109
58. Henke A., Huber S.A., Stelzner A., et al. The role of CD8 + T lymphocytes in coxsackievirus B3-induced myocarditis. J Virol 69 (1995) 6720-6728
59. Wilson F.M., Miranda Q.R., Chason J.L., et al. Residual pathologic changes following murine coxsackie A and B myocarditis. Am J Pathol 55 (1969) 253-265
60. Matsumori A., and Kawai C. An animal model of congestive (dilated) cardiomyopathy: dilatation and hypertrophy of the heart in the chronic stage in DBA/2 mice with myocarditis caused by encephalomyocarditis virus. Circulation 66 (1982) 355-360
61. Kawai C. From myocarditis to cardiomyopathy: Mechanisms of inflammation and cell death: learning from the past for the future. Circulation 99 (1999) 1091-1100
62. Godeny E.K., and Gauntt C.J. Interferon and natural killer cell activity in coxsackie virus B3-induced myocarditis. Eur Heart J 8 (1987) 433-435
63. Liu C.C., Young L.H.Y., and Young J.D.E. Mechanisms of disease: lymphocyte-mediated cytolysis and disease. N Engl J Med 335 (1996) 1651-1659
64. Gebhard J.R., Perry C.M., Harkins S., et al. Coxsackievirus B3-induced myocarditis: perforin exacerbates disease, but plays no detectable role in virus clearance. Am J Pathol 153 (1998) 417-428
65. Zaragoza C., Ocampo C., Saura M., et al. The role of inducible nitric oxide synthase in the host response to coxsackievirus myocarditis. Proc Natl Acad Sci U S A 95 (1998) 2469-2474
66. Seko Y., Tsuchimochi H., Nakamura T., et al. Expression of major histocompatibility complex class I antigen in murine ventricular myocytes infected with coxsackie virus B3. Circ Res 69 (1990) 360-367
67. Seko Y., Matsuda H., Kato K., et al. Expression of intercellular adhesion molecule-1 in murine hearts with acute myocarditis caused by coxsackievirus B3. J Clin Invest 91 (1993) 1327-1336
68. Kishimoto C., Kuribayashi K., Masuda T., et al. Immunological behavior of lymphocytes in experimental viral myocarditis: significance of T-lymphocytes in the severity of myocarditis and silent myocarditis in BALB/c-nu/nu mice. Circulation 71 (1985) 1247-1254
69. Woodruff J.F., and Woodruff J.J. Involvement of T lymphocytes in the pathogenesis of coxsackie B3 heart disease. J Immunol 113 (1974) 1726-1734
70. Kishimoto C., and Abelmann W.H. Monoclonal antibody for the prevention of acute coxsackie B3 myocarditis in mice. Circulation 79 (1989) 1300-1308
71. Kyu B., Matsumori A., Sato Y., et al. Cardiac persistence of cardioviral RNA detected by polymerase chain reaction in a murine model of dilated cardiomyopathy. Circulation 86 (1992) 1605-1614
72. Bowles N.E., Archard L.C., Olsen E.G.J., et al. Detection of coxsackie-B-virus specific RNA sequences in myocardial biopsy sample from patients with myocarditis and dilated cardiomyopathy. Lancet 1 (1986) 1120-1123
73. Schwaiger A., Umlauft F., Weyrer K., et al. Detection of enteroviral ribonucleic acid in myocardial biopsies from patients with idiopathic dilated cardiomyopathy by polymerase chain reaction. Am Heart J 126 (1993) 406-410
74. Fujioka S., Koide H., Kitaura Y., et al. Molecular detection and differentiation of enteroviruses in endomyocardial biopsies and pericardial effusions from dilated cardiomyopathy and myocarditis. Am Heart J 131 (1996) 760-765
75. Kubota T., McTiernan C.F., Frye C.S., et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 81 (1997) 627-635
76. Neu N., Rose N.R., Beisel K.W., et al. Cardiac myosin induces myocarditis in genetically predisposed mice. J Immunol 139 (1987) 3630-3636
77. Fairweather D., Lawson C.M., Chapman A.J., et al. Wild isolates of murine cytomegalovirus induce myocarditis and antibodies that cross-react with virus and cardiac myosin. Immunology 94 (1998) 263-270
78. Fairly C.K., Ryan M., Wall P.G., et al. The organisms reported to cause infective myocarditis and pericarditis in England and Wales. J Infect 32 (1996) 223-225
79. Grumbach I.M., Heim A., Pring-Akerblom P., et al. Adenoviruses and enteroviruses as pathogens in myocarditis and dilated cardiomyopathy. Acta Cardiol 54 (1999) 83-88
80. Matsumori A., Matoba Y., and Sasayama S. Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation 92 (1995) 2519-2525
81. Okabe M., Fukuda K., Arakawa K., et al. Chronic variant of myocarditis associated with hepatitis C virus infection. Circulation 96 (1997) 22-24
82. Kao J.H., and Hwang J.J. Hepatitis C virus infection and chronic active myocarditis. Circulation 98 (1998) 1044-1045
83. Dias J.C.P. Control of Chagas' disease in Brazil. Parasitol Today 3 (1987) 336-339
84. World Health Organization. Sixth program report: Chapter 6: Chagas' disease. Special Program for research and training in tropical diseases. Document TDR, PR-6, 83.6-CHA, YNDP, World Bank (1983), World Health Organization, Geneva
85. Chadrasekar B., Melby P.C., Troyer D.A., et al. Induction of proinflammatory cytokines in experimental acute Chagasic cardiomyopathy. Biochem Biophys Res Commun 223 (1996) 365-371
86. Higuchi M., Reis M.M., Aiello V.D., et al. Association of an increase in CD8 + T cells with the presence of Trypanosoma cruzi antigens in chronic, human, chagasic myocarditis. Am J Trop Med Hyg 56 (1997) 458-489
87. Williams A. Aspergillus myocarditis. Am J Pathol 61 (1974) 247-248
88. Walsh T.J., Hutchins G.M., Buckley B.H., et al. Fungal infections of the heart: analysis of 51 autopsy cases. Am J Cardiol 45 (1980) 357-366
89. Duffield J.S., Jacob A.J., and Miller H.C. Recurrent, life-threatening atrioventicular dissociation associated with toxoplasma myocarditis. Heart 76 (1996) 453-454
90. Montoya J.G., Jordan R., Lingamneni S., et al. Toxoplasmic myocarditis and polymyositis in patients with acute acquired toxoplasmosis diagnosed during life. Clin Infect Dis 24 (1997) 676-683
91. Lampert M.B., and Lang R.M. Peripartum cardiomyopathy. Am Heart J 130 (1995) 860-870
92. Huerta E.M., Erice A., Espino R.F., et al. Post-partum cardiomyopathy and acute myocarditis. Am Heart J 110 (1985) 1079-1081
93. Rizeq M.N., Rickenbacher P.R., Fowler M.B., et al. Incidents of myocarditis in peripartum cardiomyopathy. Am Heart J 74 (1994) 474-477
94. Foelich C.J., Goodwin J.S., Bankhurst A.D., et al. Pregnancy, a temporal fetal graft of suppressor cells in autoimmune disease. Am J Med 69 (1980) 329-331
95. Kovithavongs T., and Dossetor J.B. Suppressor cells in human pregnancy. Transplant Proc 10 (1978) 911-913
96. Damek D.M., and Shuster E.A. Pregnancy and multiple sclerosis. Mayo Clin Proc 72 (1997) 977-989
97. Midei M.G., DeMent S.H., Feldman A.M., et al. Peripartum myocarditis and cardiomyopathy. Circulation 81 (1990) 922-928
98. Demakis J.G., and Rahimtoola S.H. Peripartum cardiomyopathy. Circulation 44 (1971) 964-968
99. Billingham M.E. Pharmacotoxic myocardial disease: an endomyocardial study. In: Sekiguchi C., Olsen E.G.J., and Goodwin J.F. (Eds). Myocarditis and related disorders (1985), Springer-Verlag, Tokyo 278-282
100. Feenstra J., Grobbee D.E., Remme W.J., et al. Drug -induced heart failure. J Am Coll Cardiol 33 (1999) 1152-1162
101. Singal P.K., and Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 339 (1998) 900-905
102. Michels V.V., Moll P.P., Miller F.A., et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med 326 (1992) 77-82
103. Towbin J.A., Hejtmancik J.F., Brink P., et al. X-linked cardiomyopathy: molecular evidence of linkage to the Duchenne muscular dystrophy gene at the Xp21 locus. Circulation 87 (1993) 1854-1865
104. Olson T.M., Michels V.V., Thibodeau S.N., et al. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 280 (1998) 750-752
105. Kamisago M., Sharma S.D., DePalma S.R., et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 343 (2000) 1688-1696
106. Mestroni L., Rocco C., Gregori D., et al. Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. J Am Coll Cardiol 34 (1999) 181-190
107. Baig M.K., Goldman J.H., Caforio A.L.P., et al. Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relative and may represent early disease. J Am Coll Cardiol 31 (1998) 195-201
108. Michels V.V., Moll P.P., and Rodeheffer R.J. Circulating heart autoantibodies in familial as compared to with nonfamilial idiopathic dilated cardiomyopathy. Mayo Clin Proc 69 (1994) 24-27
109. Caforio A.L.P., Keeling P.J., and Zachara E. Evidence from family studies for autoimmunity in dilated cardiomyopathy. Lancet 344 (1994) 773-777
110. Kuan A.P., Chamberlain W., Malkiel S., et al. Genetic control of autoimmune myocarditis mediated by myosin-specific antibodies. Immunogenetics 49 (1999) 79-85
111. McKenna C.J., Codd K.A., McCann H.A., et al. Idiopathic dilated cardiomyopathy: familial prevalence and HLA distribution. Heart 77 (1997) 549-552
112. Albert L.J., and Inman R.D. Molecular mimicry and autoimmunity. N Engl J Med 341 (1999) 2068-2074
113. Limas C., Limas C.J., and Boudoulas H. T-cell receptor gene polymorphisms in familial cardiomyopathy: correlation with anti-β-receptor autoantibodies. Am Heart J 124 (1992) 1258-1263
114. Levine B., Kalman J., Mayer L., et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323 (1990) 236-241
115. Torre-Amione G., Kapadia S., Benedict C., et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27 (1996) 1201-1206
116. Kubota T., Alvarez R.J., Miyagishima M., et al. Expression of proinflammatory cytokines in the failing human heart: comparison of recent onset and endstage cardiomyopathy. J Heart Lung Transplant 19 (2000) 819-824
117. MacGowan G.A., Mann D.L., Kormos R.L., et al. Circulating interleukin-6 in severe heart failure. Am J Cardiol 79 (1997) 1128-1131
118. Deswal A., Bozkurt B., Seta Y., et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, enteracept) in patients with advanced heart failure. Circulation 99 (1999) 3224-3226
119. Felix S.B., Staudt A., Dorffel W.V., et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy. J Am Coll Cardiol 35 (2000) 1590-1598
120. Friman G., and Ilback N.G. Acute infection: metabolic responses, effect on performance, interaction with exercise, and myocarditis. Int J Sports Med 19 (1998) S172-S182
121. Dec G.W., Palacios I.F., Fallon J.T., et al. Active myocarditis in the spectrum of acute dilated cardiomyopathies: clinical features, histologic correlates, and clinical outcome. N Engl J Med 312 (1985) 885-890
122. Steimle A.E., Stevenson L.W., Fonarow G.C., et al. Prediction of improvement in recent onset cardiomyopathy after referral for heart transplantation. J Am Coll Cardiol 23 (1994) 553-559
123. Matsumori A., Igata H., Ono K., et al. High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity. Jpn Circ J 63 (1999) 934-940
124. Sheppard R., Bedi M., Kubota T., et al for the IMAC Investigators. Myocardial expression of Fas and recovery of left ventricular function in patients with recent-onset cardiomyopathy. J Am Coll Cardiol, in press
125. Simon M.A., Kormos R.L., Murali S., et al. Myocardial recovery using ventricular assist devices: prevalence, clinical characteristics and outcomes. Circulation, in press
126. Semigran M.J., Thaik C.M., Fifer M.A., et al. Exercise capacity and systolic and diastolic ventricular function after recovery from acute dilated cardiomyopathy. J Am Coll Cardiol 24 (1994) 462-470